Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Net Margin: 2016-2024

Historic Net Margin for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to -43.33%.

  • Akebia Therapeutics' Net Margin rose 5446.00% to 0.92% in Q3 2025 from the same period last year, while for Sep 2025 it was -7.07%, marking a year-over-year decrease of 31900.00%. This contributed to the annual value of -43.33% for FY2024, which is 47592.00% up from last year.
  • Per Akebia Therapeutics' latest filing, its Net Margin stood at -43.33% for FY2024, which was up 91.65% from -519.25% recorded in FY2023.
  • Akebia Therapeutics' Net Margin's 5-year high stood at -32.22% during FY2022, with a 5-year trough of -519.25% in FY2023.
  • Over the past 3 years, Akebia Therapeutics' median Net Margin value was -43.33% (recorded in 2024), while the average stood at -198.27%.
  • Its Net Margin has fluctuated over the past 5 years, first surged by 266,598bps in 2020, then crashed by 48,703bps in 2023.
  • Akebia Therapeutics' Net Margin (Yearly) stood at -130.61% in 2020, then slumped by 264bps to -133.25% in 2021, then soared by 10,103bps to -32.22% in 2022, then tumbled by 48,703bps to -519.25% in 2023, then spiked by 47,592bps to -43.33% in 2024.